A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
Novartis
Pfizer
National Cancer Institute (NCI)
Cancer Research UK
Nested Therapeutics, Inc
Ikena Oncology
Eli Lilly and Company
Aminex Therapeutics, Inc.
University of Southern California
Memorial Sloan Kettering Cancer Center
Deciphera Pharmaceuticals, LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Polaris Group
Case Comprehensive Cancer Center
Shenzhen BinDeBio Ltd.
BBB-Therapeutics B.V.
National Cancer Institute (NCI)
GE Healthcare
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
Duke University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center